Skip to main content

Extending the Spectrum of Precompetitive Collaboration in Oncology Research Workshop Summary (2010) / Chapter Skim
Currently Skimming:

Glossary
Pages 87-90

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 87...
... Information may come from many sources, including patient statistics, tissue specimens, genetics research, and clinical trials. Biomarker -- a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.
Read the entire page →
From page 88...
... -- "An administrative body established to protect the rights and welfare of human research subjects recruited to participate in research activities conducted under the auspices of the institution with which it is affiliated. The IRB has the authority to approve, require modification in, or disapprove all research activities that fall within its jurisdiction as specified by both the federal regulations and local institutional policy" (Department of Health and Human Services IRB Guidebook)
Read the entire page →
From page 89...
... Preclinical studies usually take place before clinical trials in humans are conducted. Precompetitive collaboration -- collaboration among competitors to achieve goals that can be more effectively accomplished by a group effort and have the potential to benefit everyone.
Read the entire page →
From page 90...
... -- a monoclonal antibody that binds to HER2 (human epidermal growth factor receptor 2) , and can kill HER2positive cancer cells.
Read the entire page →

Key Terms

  • clinical trials
  • normal cells
  • cancer cells
  • precompetitive collaboration
  • drug application

  • phase iii
  • scientific advances
  • factor receptor
  • comparative effectiveness
  • require modification

  • contain data
  • positive cancer
  • activities conducted
  • subjects recruited
  • review board

  • targeted therapy
  • treatment indications
  • specific technical
  • genetics research
  • harming normal

  • human research
  • previously approved
  • growth factor
  • marketing approval
  • administrative body

  • medical product
  • iii trials
  • technical viewpoints
  • preliminary efficacy
  • research comparing


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.